(Reuters) – Valneva climbs on the stock market on Wednesday after announcing new positive data of safety and immunogenicity of phase 2 for its candidate vaccine against Lyme disease, VLA15, which the French laboratory develops in collaboration with Pfizer.

In Paris, around 08:20 GMT, the share was up 4.65% to 3.64 euros, against a gain of 0.73% for the SBF120 at the same time.

The data follows a third dose of recall in children and adults who showed “the potential benefit that recall vaccination could have before each season of Lyme disease,” said Valneva.

According to Kempen, they clearly “demonstrate the effectiveness of annual recall doses to protect against the next seasons of ticks” and constitute “a testimony of Valneva’s solid work” in the identification of the optimal dose and the vaccination calendar to strengthen the immunogenicity of the vaccine.

“Given an attractive risk-request profile for the Lyme disease vaccine by the end of 2025, we continue to consider current valuation as an interesting point of entry,” said the broker.

Mohamed Kaabouni, analyst at Portzamparc, notes that these new data is “positive and encouraging” when the results of Phase III Valor are approached, expected for the end of the year.

In the event of clinical success, Pfizer will file a regulatory file in 2026, with a view to a marketing authorization (AMM) expected in 2027, adds Mohamed Kaabouni.

According to him, if the results are confirmed, Valneva is eligible for 143 million euros in Milestones by the possible MA.

There is currently no human vaccine against Lyme disease, Valneva declaring that VLA15 is the most advanced vaccine candidate against this disease, with two phase 3 trials in progress.

(Written by Elena Smirnova, edited by Augustin Turpin)

Copyright © 2025 Thomson Reuters